The Korean Journal of Pain

  • 제35권4호
  • /
  • Pages.440-446
  • /
  • 2022
  • /
  • 2005-9159(pISSN)
  • /
  • 2093-0569(eISSN)
대한통증학회 (The Korean Pain Society)
권호 표지
DOI QR코드

DOI QR Code

Evaluation of the antinociceptive effects of a selection of triazine derivatives in mice

  • Hajhashemi, Valiollah (Department of Pharmacology and Toxicology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences) ;
  • Khodarahmi, Ghadamali (Department of Medicinal Chemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences) ;
  • Asadi, Parvin (Department of Medicinal Chemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences) ;
  • Rajabi, Hamed (Department of Pharmacology and Toxicology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences)
  • 투고 : 2022.05.26
  • 심사 : 2022.08.12
  • 발행 : 2022.10.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: The authors showed in a previous study that some novel triazine derivatives had an anti-inflammatory effect. The present study was designed to evaluate the antinociceptive effect of five out of nine compounds including two vanillintriazine (5c and 5d) and three phenylpyrazole-triazine (10a, 10b, 10e) derivatives which showed the best anti-inflammatory effect. Methods: Male Swiss mice (25-30 g) were used. To assess the antinociceptive effect, acetic acid-writhing, formalin, and hot plate tests were used after intraperitoneal injection of each compound. Results: All compounds significantly (P < 0.001) reduced acetic acid-induced writhing at tested doses (50, 100, and 200 mg/kg). Also, the percent inhibition of writhing in the acetic acid test showed that at the maximum tested dose of these compounds (200 mg/kg), the order of potencies is as follows: 10b > 10a > 10e > 5d > 5c. In the formalin test, compounds 5d, 10a, and 10e showed an antinociceptive effect in the acute phase and all compounds were effective in the chronic phase. In the hot plate test, compounds 5c, 5d, and 10a demonstrated an antinociceptive effect. Conclusions: The results clearly showed that both vanillin-triazine and phenylpyrazole-triazine derivatives had an antinociceptive effect. Also, some compounds which showed activity in the early phase of formalin test as well as in the hot plate test could control acute pain in addition to chronic or inflammatory pain.

키워드

과제정보

This study was financially supported by Isfahan University of Medical Sciences, Isfahan, Iran (Grant no: 3400290).

참고문헌

  1. Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A comprehensive review of non-steroidal antiinflammatory drug use in the elderly. Aging Dis 2018; 9: 143-50. https://doi.org/10.14336/AD.2017.0306
  2. Claria J. Cyclooxygenase-2 biology. Curr Pharm Des 2003; 9: 2177-90. https://doi.org/10.2174/1381612033454054
  3. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000; 69: 145-82. https://doi.org/10.1146/annurev.biochem.69.1.145
  4. Gupta S, Crofford LJ. An update on specific COX-2 inhibitors: the COXIBs. Bull Rheum Dis 2001; 50: 1-4.
  5. Vishwakarma RK, Negi DS. The development of COX-1 and COX-2 inhibitors: a review. Int J Pharm Sci Res 2020; 11: 3544-55.
  6. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-55. https://doi.org/10.1001/jama.284.10.1247
  7. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-8. https://doi.org/10.1056/NEJM200011233432103
  8. Laine L. Gastrointestinal effects of NSAIDs and coxibs. J Pain Symptom Manage 2003; 25(2 Suppl): S32-40. https://doi.org/10.1016/S0885-3924(02)00629-2
  9. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332: 1302-8. https://doi.org/10.1136/bmj.332.7553.1302
  10. Arora M, Choudhary S, Singh PK, Sapra B, Silakari O. Structural investigation on the selective COX-2 inhibitors mediated cardiotoxicity: a review. Life Sci 2020; 251: 117631. https://doi.org/10.1016/j.lfs.2020.117631
  11. Salvo F, Fourrier-Reglat A, Bazin F, Robinson P, Riera-Guardia N, Haag M, et al. Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials. Clin Pharmacol Ther 2011; 89: 855-66. https://doi.org/10.1038/clpt.2011.45
  12. Olry de Labry Lima A, Salamanca-Fernandez E, Alegre Del Rey EJ, Matas Hoces A, Gonzalez Vera MA, Bermudez Tamayo C. Safety considerations during prescription of nonsteroidal anti-inflammatory drugs (NSAIDs), through a review of systematic reviews. An Sist Sanit Navar 2021; 44: 261-73. https://doi.org/10.23938/ASSN.0965
  13. White WB, Faich G, Borer JS, Makuch RW. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol 2003; 92: 411-8. https://doi.org/10.1016/S0002-9149(03)00659-3
  14. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4-15. https://doi.org/10.1172/JCI27291
  15. Marsico F, Paolillo S, Filardi PP. NSAIDs and cardiovascular risk. J Cardiovasc Med (Hagerstown) 2017; 18 Suppl 1: Special Issue on The State of the Art for the Practicing Cardiologist: The 2016 Conoscere E Curare Il Cuore (CCC) Proceedings from the CLI Foundation: e40-3. https://doi.org/10.2459/JCM.0000000000000443
  16. Sondhi SM, Dinodia M, Singh J, Rani R. Heterocyclic compounds as anti-inflammatory agents. Curr Bioact Compd 2007; 3: 91-108. https://doi.org/10.2174/157340707780809554
  17. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996; 384: 644-8. Erratum in: Nature 1997; 385: 555.
  18. Zarghi A, Arfaei S. Selective COX-2 inhibitors: a review of their structure-activity relationships. Iran J Pharm Res 2011; 10: 655-83.
  19. Sztanke K, Markowski W, Swieboda R, Polak B. Lipophilicity of novel antitumour and analgesic active 8-aryl-2,6,7,8-tetrahydroimidazo[2,1-c][1,2,4]triazine-3,4-dione derivatives determined by reversed-phase HPLC and computational methods. Eur J Med Chem 2010; 45: 2644-9. https://doi.org/10.1016/j.ejmech.2010.01.068
  20. Sztanke K, Fidecka S, Kedzierska E, Karczmarzyk Z, Pihlaja K, Matosiuk D. Antinociceptive activity of new imidazolidine carbonyl derivatives. Part 4. Synthesis and pharmacological activity of 8-aryl-3,4-dioxo-2H,8H-6,7-dihydroimidazo[2,1-c] [1,2,4]triazines. Eur J Med Chem 2005; 40: 127-34. https://doi.org/10.1016/j.ejmech.2004.09.020
  21. Asadi P, Alvani M, Hajhashemi V, Rostami M, Khodarahmi G. Design, synthesis, biological evaluation, and molecular docking study on triazine based derivatives as anti-inflammatory agents. J Mol Struct 2021; 1243: 130760. https://doi.org/10.1016/j.molstruc.2021.130760
  22. Gawade SP. Acetic acid induced painful endogenous infliction in writhing test on mice. J Pharmacol Pharmacother 2012; 3: 348. https://doi.org/10.4103/0976-500X.103699
  23. Tjolsen A, Berge OG, Hunskaar S, Rosland JH, Hole K. The formalin test: an evaluation of the method. Pain 1992; 51: 5-17. https://doi.org/10.1016/0304-3959(92)90003-T
  24. Hajhashemi V, Amin B. Effect of glibenclamide on antinociceptive effects of antidepressants of different classes. Clinics (Sao Paulo) 2011; 66: 321-5. https://doi.org/10.1590/S1807-59322011000200023
  25. Hajhashemi V, Dehdashti K. Antinociceptive effect of clavulanic acid and its preventive activity against development of morphine tolerance and dependence in animal models. Res Pharm Sci 2014; 9: 315-21.
  26. Hajhashemi V, Sajjadi SE, Zomorodkia M. Antinociceptive and anti-inflammatory activities of Bunium persicum essential oil, hydroalcoholic and polyphenolic extracts in animal models. Pharm Biol 2011; 49: 146-51. https://doi.org/10.3109/13880209.2010.504966
  27. Hunskaar S, Hole K. The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. Pain 1987; 30: 103-14. https://doi.org/10.1016/0304-3959(87)90088-1
  28. Malmberg AB, Yaksh TL. Antinociceptive actions of spinal nonsteroidal anti-inflammatory agents on the formalin test in the rat. J Pharmacol Exp Ther 1992; 263: 136-46.
  29. Choi CH, Kim WM, Lee HG, Jeong CW, Kim CM, Lee SH, et al. Roles of opioid receptor subtype in the spinal antinociception of selective cyclooxygenase 2 inhibitor. Korean J Pain 2010; 23: 236-41. https://doi.org/10.3344/kjp.2010.23.4.236
  30. Gunn A, Bobeck EN, Weber C, Morgan MM. The influence of non-nociceptive factors on hot-plate latency in rats. J Pain 2011; 12: 222-7. https://doi.org/10.1016/j.jpain.2010.06.011
  31. Malmberg AB, Bannon AW. Models of nociception: hot-plate, tail-flick, and formalin tests in rodents. Curr Protoc Neurosci 1999; 6: 8.9.1-15.
  32. Le Bars D, Gozariu M, Cadden SW. Animal models of nociception. Pharmacol Rev 2001; 53: 597-652